Research

Randomized, double-blind, placebo-controlled phase 3 study to demonstrate the efficacy and safety of milvexian, an oral factor XIa inhibitor, after a recent acute coronary syndrome.

Randomized, double-blind, placebo-controlled exploratory trial to assess the efficacy and tolerability of nerandomilast over a 24-month period when administered to individuals with interstitial lung abnormalities and a family history of pulmonary fibrosis, to reduce the risk of worsening.